PROSTATENOW™  Technical features

NCCN guidelines recommend germline testing for men with prostate cancer, and patients with a high-risk family history, intraductal histologies, or other conditions, regardless of risk. These recommendations are also for unaffected men with a family history of hereditary cancer syndromes and a family history of pathogenic mutations.

Includes both RPMs and GRS from studies involving multiple races.

PROSTATENOW™ includes all known prostate cancer susceptibility genes as well as >100 prostate cancer risk-associated SNPs for calculating GRS in multiple races. 

Comprehensive evaluation of current evidence.

PROSTATENOW™ is developed based on recommendations from up-to-date clinical guidelines, current evidence review, and proprietary data from the NorthShore team. 

Genes Tested

The core of germline testing is to know which genes/mutations have clinical validity and utility. The genes tested in PROSTATENOW™ are based on a combination of clinical guidelines and up-to-date evidence-based review as illustrated below

The most comprehensive germline panel for prostate cancer:

  • Combination of guideline and evidence-reviewed genes; total 22 genes tested for whole exons.
  • Total 223 SNPs tested to determine Genetic Risk Score (GRS)

The largest mutation database:

In addition to following the mutation-calling guidelines of American College of Medical Genetics (ACMG), we have the largest germline mutation database with data gathered from more than 300,000 men with or without prostate cancer. This information helps categorize relevant mutations in prostate cancer to provide accurate results.

We're here to guide you through the process.

Part of PROSTATENOW™ includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results. 

The technology powering PROSTATENOW™ – clinically valid and utilized.

The clinical validity and utility of RPMs and GRS in cancer risk assessment – key technology components of PROSTATENOW™ – are supported by hundreds of peer-reviewed papers published by the NorthShore team, including the following key publications in leading journals.

Group-86900@2x

Published: Nov. 28, 2020

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality

Article Conclusion:

This population-based prospective study suggests that GRS complements two guideline-recommended inherited risk measures (FH and RPMs) for stratifying the risk of PCa incidence and mortality.

Authors:

Zhuqing Shi, Elizabeth A Platz, Jun Wei, Rong Na, Richard J Fantus, Chi-Hsiung Wang, Scott E Eggener, Peter J Hulick, David Duggan, S Lilly Zheng, Kathleen A Cooney, William B Isaacs, Brian T Helfand, Jianfeng Xu

Published: Dec. 27, 2019
Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis

Article Conclusion:
This study suggests that a GRS is significantly associated with patient age at PCa diagnosis. Combining FH and GRS may better stratify inherited risk than FH alone for developing personalized PCa screening strategies.

Published: Jan. 12, 2012
Germline Mutations in HOXB13 and Prostate-Cancer Risk

Article Conclusion:
The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. (Funded by the National Institutes of Health and others.)

Published: Feb. 28, 2008
Cumulative Association of Five Genetic Variants with Prostate Cancer

Article Conclusion:
This study suggests that a GRS is significantly associated with patient age at PCa diagnosis. Combining FH and GRS may better stratify inherited risk than FH alone for developing personalized PCa screening strategies.